Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

SUMOylation participates in induction of ischemic tolerance.

Lee YJ, Castri P, Bembry J, Maric D, Auh S, Hallenbeck JM.

J Neurochem. 2009 Apr;109(1):257-67. doi: 10.1111/j.1471-4159.2009.05957.x.

2.

Dynamic interaction between WT1 and BASP1 in transcriptional regulation during differentiation.

Green LM, Wagner KJ, Campbell HA, Addison K, Roberts SG.

Nucleic Acids Res. 2009 Feb;37(2):431-40. doi: 10.1093/nar/gkn955.

3.

SUMOylation of Krüppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta.

Oishi Y, Manabe I, Tobe K, Ohsugi M, Kubota T, Fujiu K, Maemura K, Kubota N, Kadowaki T, Nagai R.

Nat Med. 2008 Jun;14(6):656-66. doi: 10.1038/nm1756.

PMID:
18500350
4.

Modification of Drosophila p53 by SUMO modulates its transactivation and pro-apoptotic functions.

Mauri F, McNamee LM, Lunardi A, Chiacchiera F, Del Sal G, Brodsky MH, Collavin L.

J Biol Chem. 2008 Jul 25;283(30):20848-56. doi: 10.1074/jbc.M710186200.

5.

Transient focal cerebral ischemia induces a dramatic activation of small ubiquitin-like modifier conjugation.

Yang W, Sheng H, Warner DS, Paschen W.

J Cereb Blood Flow Metab. 2008 May;28(5):892-6. doi: 10.1038/sj.jcbfm.9600601.

PMID:
18167501
6.

Concepts in sumoylation: a decade on.

Geiss-Friedlander R, Melchior F.

Nat Rev Mol Cell Biol. 2007 Dec;8(12):947-56. Review.

PMID:
18000527
7.

Increased protein SUMOylation following focal cerebral ischemia.

Cimarosti H, Lindberg C, Bomholt SF, Rønn LC, Henley JM.

Neuropharmacology. 2008 Feb;54(2):280-9.

PMID:
17991493
8.
9.

Small ubiquitin-related modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs.

Mikolajczyk J, Drag M, Békés M, Cao JT, Ronai Z, Salvesen GS.

J Biol Chem. 2007 Sep 7;282(36):26217-24.

10.

Transient global cerebral ischemia induces a massive increase in protein sumoylation.

Yang W, Sheng H, Warner DS, Paschen W.

J Cereb Blood Flow Metab. 2008 Feb;28(2):269-79.

PMID:
17565359
11.

Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation.

Knipscheer P, van Dijk WJ, Olsen JV, Mann M, Sixma TK.

EMBO J. 2007 Jun 6;26(11):2797-807.

12.

Inhibition of DNA binding of Sox2 by the SUMO conjugation.

Tsuruzoe S, Ishihara K, Uchimura Y, Watanabe S, Sekita Y, Aoto T, Saitoh H, Yuasa Y, Niwa H, Kawasuji M, Baba H, Nakao M.

Biochem Biophys Res Commun. 2006 Dec 29;351(4):920-6.

PMID:
17097055
13.

Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways.

Li T, Santockyte R, Shen RF, Tekle E, Wang G, Yang DC, Chock PB.

J Biol Chem. 2006 Nov 24;281(47):36221-7.

14.
15.

Cerebral preconditioning and ischaemic tolerance.

Gidday JM.

Nat Rev Neurosci. 2006 Jun;7(6):437-48. Review.

PMID:
16715053
16.

Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes.

Bossis G, Melchior F.

Mol Cell. 2006 Feb 3;21(3):349-57.

17.

Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons.

Meller R, Cameron JA, Torrey DJ, Clayton CE, Ordonez AN, Henshall DC, Minami M, Schindler CK, Saugstad JA, Simon RP.

J Biol Chem. 2006 Mar 17;281(11):7429-36.

18.

A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation.

Owerbach D, McKay EM, Yeh ET, Gabbay KH, Bohren KM.

Biochem Biophys Res Commun. 2005 Nov 18;337(2):517-20.

PMID:
16198310
19.
20.

SUMO: a history of modification.

Hay RT.

Mol Cell. 2005 Apr 1;18(1):1-12. Review.

Items per page

Supplemental Content

Support Center